Advanced search
Add to list

The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper

(2009) ALLERGY. 64(12). p.1737-1745
Author
Organization
Abstract
The methodology of randomized clinical trials is essential for the critical assessment and registration of therapeutic interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement was developed to alleviate the problems arising from the inadequate reporting of randomized controlled trials. The present article reflects on the items that we believe should be included in the CONSORT checklist in the context of conducting and reporting trials in allergen-specific immunotherapy. Only randomized, blinded (in particular blinding of patients, health care providers, and outcome assessors), placebo-controlled Phase III studies in this article. Our analysis focuses on the definition of patients' inclusion and exclusion criteria, allergen standardization, primary, secondary and exploratory outcomes, reporting of adverse events and analysis.
Keywords
specific immunotherapy, Ga2len, randomized controlled trial, Consort

Citation

Please use this url to cite or link to this publication:

MLA
Bousquet, PJ et al. “The CONSORT Statement Checklist in Allergen-specific Immunotherapy: a GA2LEN Paper.” ALLERGY 64.12 (2009): 1737–1745. Print.
APA
Bousquet, P., Brozek, J., Bachert, C., Bieber, T., Bonini, S., Burney, P., Calderon, M., et al. (2009). The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. ALLERGY, 64(12), 1737–1745.
Chicago author-date
Bousquet, PJ, J Brozek, Claus Bachert, T Bieber, Sergio Bonini, Peter Burney, M Calderon, et al. 2009. “The CONSORT Statement Checklist in Allergen-specific Immunotherapy: a GA2LEN Paper.” Allergy 64 (12): 1737–1745.
Chicago author-date (all authors)
Bousquet, PJ, J Brozek, Claus Bachert, T Bieber, Sergio Bonini, Peter Burney, M Calderon, Giorgio W Canonica, E Compalati, JP Daures, L Delgado, P Demoly, R Dahl, SR Durham, ML Kowalski, HJ Malling, H Merk, N Papadopoulos, G Passalacqua, HU Simon, M Worms, Ulrich Wahn, Torsten Zuberbier, HJ Schünemann, and Jean Bousquet. 2009. “The CONSORT Statement Checklist in Allergen-specific Immunotherapy: a GA2LEN Paper.” Allergy 64 (12): 1737–1745.
Vancouver
1.
Bousquet P, Brozek J, Bachert C, Bieber T, Bonini S, Burney P, et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. ALLERGY. USA: WILEY-BLACKWELL PUBLISHING, INC, COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA; 2009;64(12):1737–45.
IEEE
[1]
PJ Bousquet et al., “The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper,” ALLERGY, vol. 64, no. 12, pp. 1737–1745, 2009.
@article{977309,
  abstract     = {The methodology of randomized clinical trials is essential for the critical assessment and registration of therapeutic interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement was developed to alleviate the problems arising from the inadequate reporting of randomized controlled trials. The present article reflects on the items that we believe should be included in the CONSORT checklist in the context of conducting and reporting trials in allergen-specific immunotherapy. Only randomized, blinded (in particular blinding of patients, health care providers, and outcome assessors), placebo-controlled Phase III studies in this article. Our analysis focuses on the definition of patients' inclusion and exclusion criteria, allergen standardization, primary, secondary and exploratory outcomes, reporting of adverse events and analysis.},
  author       = {Bousquet,  PJ and Brozek, J and Bachert, Claus and Bieber, T and Bonini, Sergio and Burney, Peter and Calderon, M and Canonica, Giorgio W and Compalati, E and Daures, JP and Delgado, L and Demoly, P and Dahl, R and Durham, SR and Kowalski, ML and Malling, HJ and Merk, H and Papadopoulos, N and Passalacqua, G and Simon, HU and Worms, M and Wahn, Ulrich and Zuberbier, Torsten and Schünemann, HJ and Bousquet, Jean },
  issn         = {0105-4538},
  journal      = {ALLERGY},
  keywords     = {specific immunotherapy,Ga2len,randomized controlled trial,Consort},
  language     = {eng},
  number       = {12},
  pages        = {1737--1745},
  publisher    = {WILEY-BLACKWELL PUBLISHING, INC, COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA},
  title        = {The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper},
  url          = {http://dx.doi.org/10.1111/j.1398-9995.2009.02232.x},
  volume       = {64},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: